Abbott India growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+8.1%+9.6%+9.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+11.7%+16.6%+20.5%
+11.9%+17.4%+21.7%
+9.7%+17.8%+26.5%
——+26.5%
+9.9%+13.9%+14.0%
+12.8%+14.4%+16.0%
+30.4%−16.6%+35.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ABBOTINDIA₹26,145.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—+9.4+9.6+8.1
EBITDA Growth—+20.5+16.6+11.7
EBIT Growth—+21.7+17.4+11.9
Net Income Growth—+26.5+17.8+9.7
EPS Growth—+26.5——
Total Assets Growth—+14.0+13.9+9.9
Total Equity Growth—+16.0+14.4+12.8
Cash from Operations Growth—+35.8-16.6+30.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.